{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T06:02:49Z","timestamp":1789624969280,"version":"build-2803163510"},"reference-count":27,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,4,7]],"date-time":"2015-04-07T00:00:00Z","timestamp":1428364800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.clinthera.2015.03.021","type":"journal-article","created":{"date-parts":[[2015,4,18]],"date-time":"2015-04-18T02:58:22Z","timestamp":1429325902000},"page":"1317-1328.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Economic Comparison of an Empirical Versus Diagnostic-Driven Strategy for Treating Invasive Fungal Disease in Immunocompromised Patients"],"prefix":"10.1016","volume":"37","author":[{"given":"Rosemary","family":"Barnes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Earnshaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raoul","family":"Herbrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orla","family":"Morrissey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Slavin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3879-0549","authenticated-orcid":false,"given":"Eric","family":"Bow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"McDade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudie","family":"Charbonneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Weinstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Kantecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haran","family":"Schlamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Maertens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2015.03.021_bib1","doi-asserted-by":"crossref","first-page":"4358","DOI":"10.1182\/blood-2002-05-1496","article-title":"Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors","volume":"100","author":"Marr","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2015.03.021_bib2","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1128\/AAC.01423-10","article-title":"Attributable hospital cost and antifungal treatment of invasive fungal diseases in high-risk hematology patients: an economic modeling approach","volume":"55","author":"Ananda-Rajah","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2015.03.021_bib3","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3324\/haematol.11665","article-title":"Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology","volume":"94","author":"Cornely","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.clinthera.2015.03.021_bib4","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1093\/jac\/dku506","article-title":"Prospective evaluation of the cost of diagnosis and treatment of invasive fungal disease in a cohort of adult haematology patients in the UK","volume":"70","author":"Ceesay","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2015.03.021_bib5","doi-asserted-by":"crossref","first-page":"47","DOI":"10.4103\/0976-500X.124423","article-title":"Evaluation of treatment of invasive fungal infections","volume":"5","author":"Casucci","year":"2014","journal-title":"J Pharmacol Pharmacother"},{"key":"10.1016\/j.clinthera.2015.03.021_bib6","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1586\/erp.13.3","article-title":"Pharmacoeconomics of empirical antifungal use in febrile neutropenic hematological malignancy and hematopoietic stem cell transplant patients","volume":"13","author":"Turner","year":"2013","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.clinthera.2015.03.021_bib7","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1086\/496927","article-title":"Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study","volume":"41","author":"Maertens","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2015.03.021_bib8","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1086\/597395","article-title":"Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial","volume":"48","author":"Cordonnier","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2015.03.021_bib9","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/bmt.2008.355","article-title":"A prospective randomized controlled trial comparing PCR-based and empirical treatment with liposomal amphotericin B in patients after allo-SCT","volume":"43","author":"Hebart","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clinthera.2015.03.021_bib10","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2009.21.8032","article-title":"Clinically driven diagnostic antifungal approach in neutropenic patients: a prospective feasibility study","volume":"28","author":"Girmenia","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2015.03.021_bib11","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.3324\/haematol.2011.042598","article-title":"The use and efficacy of empirical versus pre-emptive therapy in the management of fungal infections: the HEMA e-Chart Project","volume":"96","author":"Pagano","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.clinthera.2015.03.021_bib12","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1473-3099(13)70076-8","article-title":"Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients: a randomised controlled trial","volume":"13","author":"Morrissey","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.clinthera.2015.03.021_bib13","doi-asserted-by":"crossref","unstructured":"Hahn-Ast C, Glasmacher A, M\u00fcckter S, et al. Overall survival and fungal infection-related mortality in patients with invasive fungal infection and neutropenia after myelosuppressive chemotherapy in a tertiary care centre from 1995 to 2006. J Antimicrob Chemother. 2010;65:761-768.","DOI":"10.1093\/jac\/dkp507"},{"key":"10.1016\/j.clinthera.2015.03.021_bib14","unstructured":"Accord Healthcare Limited. Fluconazole 100 mg capsules Summary of Product Characteristics, 2012. http:\/\/www.medicines.org.uk\/emc\/medicine\/25923\/SPC\/Fluconazole+100mg+Capsules\/. Accessed May 9, 2013."},{"key":"10.1016\/j.clinthera.2015.03.021_bib15","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/bmt.2011.178","article-title":"ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients","volume":"47","author":"Marchetti","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clinthera.2015.03.021_bib16","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJM199903113401004","article-title":"Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group","volume":"340","author":"Walsh","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2015.03.021_bib17","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJM200201243460403","article-title":"Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever","volume":"346","author":"Walsh","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2015.03.021_bib18","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1056\/NEJMoa040446","article-title":"Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia","volume":"351","author":"Walsh","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2015.03.021_bib19","unstructured":"BMJ Group and Pharmaceutical Press. British National Formulary 2012, 2012. www.medicinescomplete.com. Accessed December 11, 2012."},{"key":"10.1016\/j.clinthera.2015.03.021_bib20","unstructured":"E.R. Squibb & Sons Limited. Amphotericin (Fungizone) Summary of Product Characteristics, 2010. www.medicines.org.uk\/emc\/medicine\/559\/SPC."},{"key":"10.1016\/j.clinthera.2015.03.021_bib21","unstructured":"Gilead Sciences Limited. Liposomal amphotericin (AmBisome) Summary of Product Characteristics. 2011."},{"key":"10.1016\/j.clinthera.2015.03.021_bib22","unstructured":"Merck Sharp & Dohme Limited. Caspofungin (Cancidas) Summary of Product Characteristics. 2012."},{"key":"10.1016\/j.clinthera.2015.03.021_bib23","unstructured":"Pfizer Limited. Voriconazole (VFEND 50 mg and 200 mg film-coated tablets, VFEND 200 mg powder for solution for infusion, VFEND 40 mg\/mL powder for oral suspension) Summary of Product Characteristics. 2013."},{"key":"10.1016\/j.clinthera.2015.03.021_bib24","unstructured":"Joint Health Surveys Unit. Health Survey for England, 2010, 2011. https:\/\/catalogue.ic.nhs.uk\/publications\/public-health\/surveys\/heal-surv-tren-tabl-2010\/hse-tren-comm-2010-rep1.pdf. Accessed March 11, 2013."},{"key":"10.1016\/j.clinthera.2015.03.021_bib25","unstructured":"Curtis L. Units Costs of Health and Social Care, 2012. http:\/\/kar.kent.ac.uk\/32408\/1\/full-with-covers.pdf. Accessed March 11, 2013."},{"key":"10.1016\/j.clinthera.2015.03.021_bib26","unstructured":"Department of Health. NHS Trusts and PCTs combined reference cost schedules 2010-2011, 2011. www.dh.gov.uk\/en\/Publicationsandstatistics\/Publications\/PublicationsPolicyAndGuidance\/DH_131140. Accessed September 20, 2012."},{"key":"10.1016\/j.clinthera.2015.03.021_bib27","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1086\/513943","article-title":"Invasive aspergillosis","volume":"26","author":"Denning","year":"1998","journal-title":"Clin Infect Dis"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291815001630?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291815001630?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T12:10:30Z","timestamp":1668600630000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291815001630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S0149291815001630"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2015.03.021","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Economic Comparison of an Empirical Versus Diagnostic-Driven Strategy for Treating Invasive Fungal Disease in Immunocompromised Patients","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2015.03.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}